10x Genomics Cash Flow Statement
NASDAQ: TXGIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
80.65+3.37 (+4.36%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
10x Genomics free cash flow
In fiscal 2025, 10x Genomics generated $136.1 million of operating cash flow and spent $5.9 million on capital expenditures. That left free cash flow of $130.1 million, a free-cash-flow margin of 20.2% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
10x Genomics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -43.54M | -182.63M | -255.10M | -166.00M | -58.22M | -542.73M | -31.25M | -112.48M | -18.76M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 36.20M | 35.88M | 35.51M | 25.37M | 21.12M | 14.01M | 7.07M | 3.90M | 4.30M |
| Stock-Based Compensation | 109.12M | 140.75M | 166.95M | 136.85M | 95.96M | 48.63M | 13.33M | 2.66M | 1.66M |
| Change in Working Capital | 68.58M | 23.95M | 1.50M | -30.01M | -50.51M | -40.88M | -6.70M | -15.22M | -2.74M |
| Operating Cash Flow | 136.05M | 6.66M | -15.20M | -33.61M | -21.37M | -217.90M | 34.63M | -76.41M | -10.70M |
| Capital Expenditures | -5.93M | -12.39M | -48.60M | -131.66M | -101.28M | -36.67M | -42.74M | -6.28M | -3.76M |
| Investing Cash Flow | -13.44M | -32.63M | 133.49M | -350.89M | -106.73M | -38.39M | -42.77M | -6.71M | -3.76M |
| Share Repurchases | — | — | — | — | — | — | — | — | -80.00K |
| Debt Issued | — | — | — | — | — | 0 | 0 | 19.51M | — |
| Debt Repaid | — | — | — | 0 | 0 | -31.26M | 0 | -704.00K | — |
| Financing Cash Flow | 6.80M | 10.91M | 13.67M | 15.82M | 35.30M | 468.91M | 414.59M | 105.37M | 20.58M |
| Net Change in Cash | 129.90M | -15.22M | 131.93M | -368.72M | -92.57M | 212.15M | 406.40M | 22.23M | 6.11M |
| Free Cash Flow | 130.12M | -5.73M | -63.80M | -165.27M | -122.65M | -254.56M | -8.12M | -82.69M | -14.46M |
This table shows 9 annual periods of 10x Genomics's cash flow statement, from FY 2025 back to FY 2017, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TXG's reporting calendar. What is a cash flow statement?